$0.55
+0.03 (+6.81%)
Open$0.55
Previous Close$0.51
Day High$0.55
Day Low$0.51
52W High$3.13
52W Low$0.58
Volume—
Avg Volume357.6K
Market Cap22.19M
P/E Ratio—
EPS$-1.19
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+755.1% upside
Current
$0.55
$0.55
Target
$4.68
$4.68
$2.81
$4.68 avg
$5.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 20.64M | 21.15M | 3.13M |
| Net Income | -16,572,079 | -15,283,196 | -134,676 |
| Profit Margin | -80.3% | -76.3% | -4.3% |
| EBITDA | -16,572,079 | -16,132,262 | -218,349 |
| Free Cash Flow | — | — | -122,296 |
| Rev Growth | -2.4% | -2.4% | +0.4% |
| Debt/Equity | — | — | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |